Cocrystal’s COVID-19 antiviral CDI-45205 shown to be active against SARS-CoV-2 and prominent SARS-CoV-2 variants
On Jun. 14, 2021, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development against coronaviruses including SARS-CoV-2, the virus that causes COVID-19.
Tags:
Source: Cocrystal Pharma
Credit:
